Skip to main content
. Author manuscript; available in PMC: 2018 Dec 28.
Published in final edited form as: Nat Rev Clin Oncol. 2014 Oct 14;11(11):630–632. doi: 10.1038/nrclinonc.2014.174

Figure 1 |.

Figure 1 |

Adoptive cell transfer immunotherapy. Cells are obtained from a resected tumour (autologous TILs) or using peripheral lymphocytes genetically engineered to express antitumour T-cell receptors, expanded in vitro and infused to patients after they have received a preparative lymphodepleting regimen. Abbreviation: TIL, tumour-infiltrating lymphocyte.